Hamza Suria - 10 Feb 2022 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
President, CEO, Director
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
10 Feb 2022
Net transactions value
$0
Form type
4
Filing time
14 Feb 2022, 15:49:27 UTC
Previous filing
22 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 10 Feb 2022 Common Stock 200,000 $30.44 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F2 In addition to the remaining options to purchase 200,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.